Technology | August 30, 2013

FDA Clears PFM Medical’s Transcatheter Patent Ductus Arteriosus Occlusion Device

PFM Medical

August 30, 2013 — PFM Medical received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Nit-Occlud Patent Ductus Arteriosus (PDA) device. Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter less than 4 mm.

A catheter containing the occluder is threaded into a vein in the groin and through the pulmonary artery. It is then advanced through the defect. When it is in the correct position, the coil is advanced through the catheter into the aorta. The coil wire is then released so that the last loop is on the pulmonary side of the defect.

The Nit-Occlud PDA device functions as a “plug” (occluder) to close an abnormal opening between the pulmonary artery and the aorta. The occluder is made of a self-expanding coil spiral that consists of an inner (core) wire tightly wrapped by an outer coil wire. After the device is in place, tissue will grow over it and the device then becomes part of the pulmonary artery.

This device can prevent blood from passing through the PDA, which may cause symptoms such as fatigue, difficult or rapid breathing, failure to grow normally, or chronic respiratory infections such as colds and pneumonia. Large openings can lead to heart failure and death. The device is implanted without the use of open-heart surgery.

A Phase II clinical study was conducted with 378 subjects enrolled in 15 study centers throughout the United States under an investigational device exemption (IDE) to establish a reasonable assurance of safety and effectiveness of the Nit-Occlud PDA. Favorable results meeting all objective performance criteria from this clinical study were the basis for the premarket approval decision.

For more information: www.pfmmedical.com

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
wearable defibrillators prevent sudden cardiac death in pediatric patients
Feature | Sudden Cardiac Arrest| May 11, 2017
May 11, 2017 — A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in
pediatric cardiomyopathy, management, clinical outcomes, NIH study, Circulation Heart Failure, Children's Hospital of Michigan
News | Congenital Heart| April 04, 2017
A multi-center study done in the United States and Canada may have global applicability for families with children...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Echopixel, True 3D Viewer, interactive virtual reality, pediatric surgery, increased clinical adoption
News | Advanced Visualization| March 21, 2017
March 21, 2017 — EchoPixel recently announced progress in the clinical adoption of its True 3D...
Melody transcatheter pulmonary valve, FDA expands indication, Melody for use in replacing failed surgical valves
Technology | Heart Valve Technology| March 14, 2017
March 14, 2017 — The United States Food and Drug Administration (FDA) has expanded use of the Medtronic Melody Transc
Stratasys, 3DHEART trial, open enrollment, 3-D printed pediatric heart models
News | 3-D Printing| March 13, 2017
Stratasys Ltd. announced last week enrollment is now open for 3DHEART, an investigator-initiated trial. 3DHEART, which...
Philips, Phoenix Children's Hospital, strategic partnership, congenital heart
News | Congenital Heart| March 07, 2017
Philips and Phoenix Children’s Hospital (Arizona) announced a long-term strategic partnership with a total value of up...
Overlay Init